LANSING, MI — (Marketwire) — 11/03/11 — Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (KBLB) (the “Company” or “Kraig”) announced that it signed a commercial license agreement with the University of Notre Dame regarding spider silk technologies.

The agreement awards Kraig the exclusive worldwide commercial rights to certain spider silk technologies which the Company jointly developed with the University of Notre Dame. Pursuant to the agreement, the University of Notre Dame will become a shareholder of the Company. The University will also receive a 2% royalty of the Company’s net sales of products which incorporate the technology.

The subject of the agreement is the definitive spelling out of rights for the commercialization of what the Company refers to as “generation one” spider silk technology. The agreement confirms the Company’s exclusive right to the commercial development of spider silk textiles derived from the subject technology.

“Due to the significance of this technology it was important that we craft an agreement that benefits Kraig, our shareholders and the University,” stated Kim Thompson, Company CEO and founder. “We are very happy to welcome the University of Notre Dame as our newest shareholder. We are also very happy to formally consummate this commercial license agreement covering the commercial rights to this exciting technology which we have been developing with the University.”

“Our collaboration with university laboratories has been fundamental to the rapid progress we have made in the development of spider silk,” Thompson continued. “The commercial license agreement reflects that sentiment and lays the groundwork for the Company’s commercialization of spider silk technologies.”

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com) is a fully reporting biotechnology company that recently achieved a series of scientific breakthroughs, with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “develops,” “researching,” “research,” “potential,” “could” or other words or phrases of similar import. Similarly, statements in this release that describe the Company’s business strategy, outlook, objectives, plans, intentions or goals should all be considered forward-looking statements. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. Management cautions that its ability to further its research, and create commercially-viable products may be affected by the competitive environment, the Company’s financial condition and its ability to raise sufficient capital to meet the financial obligations of its business plan and to fund its continuing operations.

This press release does not constitute an offer to sell or the solicitation of an offer to buy any security and shall not constitute an offer, solicitation or sale of any securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction.

Contacts:

Ben Hansel
Hansel Capital
Email Contact
(720) 288-8495

LANSING, MI — (Marketwire) — 08/08/11 — Kraig Biocraft Laboratories, Inc. (KBLB) announced that researchers working with the Company recently completed the second round of micro-insertions using zinc finger technology. The use of the zinc finger technology in the second round is designed to further enhance Kraig’s previously disclosed Monster Silk polymers.

“This round of micro-insertions is focused on further modifying and advancing the capabilities of our ‘Monster Silk’ caterpillars,” said CEO Kim Thompson. “In the second round, the zinc finger technology is being used to modify one of the company’s transgenic lines of silk worm that are already producing recombinant spider silk. This work represents a significant step forward from our first round of zinc finger micro-insertions.

“We are so confident in the technology,” continued Thompson, “that we advanced to the second round of micro-insertions even while we are still awaiting a definitive report on the first round.”

The current second round is focused on two objectives: 1) modifying the profile of the expressed proteins in the previously disclosed “Monster Silk” fiber, and 2) potentially creating a new recombinant silk platform technology.

“We are very happy to see this work progressing so quickly,” said Thompson. “As I have previously noted, we are monitoring the results of round one, and now of round two, very closely. We are very optimistic that we will be able to announce results from the first round in early Fall, and results from the second round, in approximately the middle to late Fall.”

In April, Kraig entered into an agreement with Sigma-Aldrich to use Sigma’s powerful zinc finger technology to accelerate Kraig’s scientific research and product development. The zinc fingers are an effective genetic engineering technology that the Company is using to create the next generation of biomaterials, including recombinant spider silks, for the textile and technical textile markets.

About Kraig Biocraft Laboratories
Kraig Biocraft Laboratories is a fully reporting biotechnology company that recently achieved a series of scientific breakthroughs, with implications for the global textile industry. For further information, please visit www.KraigLabs.com.

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “develops,” “researching,” “research,” “potential,” “could” or other words or phrases of similar import. Similarly, statements in this release that describe the Company’s business strategy, outlook, objectives, plans, intentions or goals should all be considered forward-looking statements. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. Management cautions that its ability to further its research, and create commercially-viable products may be affected by the competitive environment, the Company’s financial condition and its ability to raise sufficient capital to meet the financial obligations of its business plan and to fund its continuing operations.

Contact:

Ben Hansel, Hansel Capital, LLC
(720) 288-8495

The Company’s First Zinc Finger Technology Silkworms Achieve High Hatch Rate

LANSING, MI — (Marketwire) — 07/05/11 — Kraig Biocraft Laboratories, Inc. (KBLB) announced the completion of its first round of zinc finger micro-insertions.

“We are very excited to be performing these genetic engineering feats so soon after signing the agreement for their use with Sigma-Aldrich,” said CEO and company founder, Kim K. Thompson. “The immediate results from this first round of generic insertion are truly encouraging, as we observed a high hatch rate within a few days of employing the new technology.”

In April, Kraig entered into an agreement with Sigma-Aldrich to use Sigma’s powerful zinc finger technology to accelerate Kraig’s scientific research and product development. The zinc fingers are an effective genetic engineering technology that the Company is using to create the next generation of biomaterials, including recombinant spider silks, for the textile and technical textile markets.

“The company has very high expectations for these newly hatched silkworms and we are watching their development closely,” Thompson continued. “As of yet, the caterpillars are far too small for us to determine whether we hit our genetic target. So far, the technology is performing as anticipated and, even as we monitor the development of these silkworms, we are preparing for the next round of micro-insertions.”

About Kraig Biocraft Laboratories

Kraig Biocraft Laboratories is a fully reporting biotechnology company that recently achieved a series of scientific breakthroughs, with implications for the global textile industry. For further information, please visit www.KraigLabs.com.

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “develops,” “researching,” “research,” “potential,” “could” or other words or phrases of similar import. Similarly, statements in this release that describe the Company’s business strategy, outlook, objectives, plans, intentions or goals should all be considered forward-looking statements. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. Management cautions that its ability to further its research, and create commercially-viable products may be affected by the competitive environment, the Company’s financial condition and its ability to raise sufficient capital to meet the financial obligations of its business plan and to fund its continuing operations.

Contact:
Ben Hansel, Hansel Capital, LLC
(720) 288-8495

LANSING, MI — (Marketwire) — 06/30/11 — Kraig Biocraft Laboratories, Inc. (KBLB) announced that the Company has entered into a new financing agreement with Calm Seas Capital.

The new credit facility supplements the existing agreement with Calm Seas Capital and provides for up to $1.5 million over a 24 month period.

“Calm Seas has been a solid funding source and their new expanded capital commitment strengthens Kraig’s position, as we move forward,” stated Kim Thompson, the Company’s CEO and founder. “The new credit facility signifies an important step in executing our commercialization plan and the proceeds will enhance our capacity to pursue the ramp-up phase of our recombinant product.”

The financing agreement with Calm Seas Capital was recently disclosed in an 8k filing and that filing, including details of the agreement, are available on the EDGAR system.

About Kraig Biocraft Laboratories

Kraig Biocraft Laboratories is a fully reporting biotechnology company that recently achieved a series of scientific breakthroughs with implications for the global textile industry. For further information, please visit www.KraigLabs.com.

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “develops,” “researching,” “research,” “potential,” “could” or other words or phrases of similar import. Similarly, statements in this release that describe the Company’s business strategy, outlook, objectives, plans, intentions or goals should all be considered forward-looking statements. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. Management cautions that its ability to further its research, and create commercially-viable products may be affected by the competitive environment, the Company’s financial condition and its ability to raise sufficient capital to meet the financial obligations of its business plan and to fund its continuing operations.

Contact:
Ben Hansel, Hansel Capital, LLC
(720) 288-8495

June 2011

Mark Marek of Chartpoppers.com: Hello, welcome to Chartpoppers. Today we’re joined by CEO Kim Thompson of Kraig Biocraft Laboratories. Kraig Biocraft Laboratories trades, and is quoted on the Over the Counter QB, under the symbol KBLB.

Kim, thanks for coming back to the show and updating us on the company.

Kim Thompson, CEO and founder, Kraig Biocraft Laboratories, Inc.: It’s my pleasure Mark.

MM: Kim, we do appreciate you taking the time out.

I know that you’re a very busy man. You get a lot of calls since you cracked the code, but could you maybe spend a little time and tell us about how things have progressed since you made that announcement about six months ago and what developments have been in the Company?

KT: Absolutely, for your listeners who may not be familiar with the Company let me give a little bit of recap. In fact, when we last did an interview, Mark, it was shortly before we made that announcement with the University of Notre Dame and, essentially, what Kraig Biocraft Laboratories has been doing for the last several years, is working cooperatively with the University of Notre Dame to produce recombinant silk fibers.

Essentially, what we’re doing is genetic engineering work, to try to create a platform for industrial scale production of recombinant silk fibers with similar mechanical characteristics to those found in nature, in spider silk. A material which is stronger, tougher than steel, highly flexible, which has physical and mechanical properties which are, in some ways, unmatched by materials which man can currently produce, and we really, I’m happy to say, back in September we were able to announce that we had largely achieved those goals.

In working cooperatively with the University, we were able to announce that we created approximately twenty different strains of transgenic silkworm, which we created using spider silk DNA sequences and that these silkworms were spinning recombinant silk, which was a fusion of spider silk and native silkworm silk and we announced, also at that joint press conference, that one of these silks, in particular, which we are tentatively calling “Monster Silk” was demonstrating physical properties of strength and elasticity, which significantly exceed that of natural silkworm silk. So, this was a major milestone for the Company, but a lot has happened since then.

What I can now reveal here in this interview, because we actually issued a press release about it, is that shortly after that announcement we entered into negotiations with one of the world’s largest and most powerful biotechnology companies, Sigma-Aldrich, and we entered into negotiations with them in order to acquire licensing rights to use their very powerful Zinc Finger technology in our laboratories.

It’s taken months to finalize that agreement, but we actually signed with them on April 8 and we are now introducing the Zinc Finger technology into our laboratory.

Sigma is currently designing and building customized Zinc Fingers for our use and this is and incredibly powerful technology, which will greatly accelerate our research and development efforts and also give us capabilities, which simply would have been impossible with any other technology.

It’s also, from our perspective, something of a stamp of approval. Sigma came in and did due diligence on our Company, sent scientists into our lab to make sure our technology was solid before signing the deal with us and that was really the first time we let an outside company come in and actually put a scientist in our lab and review what we’ve done and what we’ve accomplished.

That was a very big deal for us. Sigma’s now a minor shareholder of Kraig Biocraft Laboratories, as a result of this transaction, and we do anticipate that it will rapidly speed up our development of the next generation of products.

MM: Kim, could give us a little more understanding in what the technology that Life Science brings to the table enables you to do?

KT: To describe this technology that we’ve acquired through this licensing agreement with Sigma, it’s going to be little difficult for those who aren’t intimately familiar with the workings of biotechnology, but, in essence, and, this going to be a little more detailed than you want, but, in essence, this technology, this Zinc-Finger technology with Sigma, will allow us for the first time to make changes in the silkworm DNA that were completely impossible to make before. In the past, these genetic engineering technologies were almost like throwing darts at a gigantic dart board from a distance of, maybe, 200 yards and, in order the make the changes that you wanted, you would have to throw those darts really hard. You might have to throw 10,000 of them to get even close to your target and you probably would never get exactly get to your target, but you could get close. With 10,000 tries you might get lucky and get close.

With this Zinc-Finger technology, it’s actually possible to walk right up to the dart board and push the dart in exactly where you want it the first try; the very first try.

To say that, and this is just my own thinking, but my own thinking here is that this will accelerate our product development by a factor of 50.

Instead of 10,000 tries to create a new recombinant silk fiber with extraordinary properties, we should be able to design the sequence, walk up to that dartboard and make that edit, make that change.

It’s almost like editing a document in Microsoft Word. Go into the document, you see a word that’s misspelled, you can change it. You want to change a period to a question mark, you can change it.

For the first time, this technology will give us the ability to do that with silkworm DNA. So, it’s incredibly powerful. We’re very excited. The deal’s almost been six months in the works, but it’s six months that I think are really going to pay off for Kraig Labs and its shareholders.

MM: Back in December 2010 you released a video, which deals with the basic technology of spider silk. I think it’s important to mention that, because it could be a little hard to wrap your hands around the significance of these findings. Could you maybe give us a link or direction to that video?

KT: Probably the best, there have been several videos that we produced or that have been produced by, for example, the University of Notre Dame, on this technology. I would suggest going to the Company’s website and going to our news page or our video page. There you can find links to several news stories and videos describing what we’re doing. All of those videos predate the signing of Sigma deal, but you can certainly get an idea of the nature of the technology and what it is that we’ve accomplished, and what we’re doing.

The website is www.KraigLabs.com . Those videos are available there and what you can see on those videos is actual silk fibers that we’ve produced, the recombinant silk fibers, using spider silk DNA.

You can see the genetic engineering technologies. You can see our genetically modified silkworms and, of course, you can see me and some of the scientists that have been working at Notre Dame on this project for the last several years.

I know, to many people who just learned Kraig Labs since September, it appears like we arrived on the scene overnight and we formed a company and created this transgenic silkworm, but it’s actually been many, many years in the works.

There’s been a lot of elbow work. A lot of hard work and effort by Kraig Labs and the University of Notre Dame to bring us to where we are now, which is a point where we actually have not just research and development, but actual product and are gearing up towards actual commercialization.

MM: Again, the Company is Kraig Biocraft Laboratories. The symbol can be found on the Over the Counter QB, under the symbol KBLB.

Kim, we’re very excited to be following the Company during this crucial time. It’s been a pleasure and thanks for speaking with us and we look forward to checking in a few months and just see where you are with the spider silk.

KT: Mark, it’s been a pleasure, and we haven’t forgotten that you came to interview us, even before we had the breakthrough announcement in September.

You know, since that time, we’ve obviously garnered a lot of interest and we received a lot of calls, but before that breakthrough announcement, we were relatively obscure and we haven’t forgotten that you initiated some coverage of us before we were known and it’s been a please to do another interview with you.

MM: Thank you very much, Kim. Have a good day.

Independent Testing Confirms That the New Hybrids Are Producing Recombinant Silk Which Significantly Exceeds Traditional Silk in Both Elasticity and Tensile Strength

LANSING, MI, May 31, 2011 (MARKETWIRE via COMTEX) — Kraig Biocraft Laboratories, Inc. (PINKSHEETS: KBLB) announced that it successfully mated its transgenic silkworms, which produce recombinant spider silk, with a physically larger commercial strain of the domesticated silkworm. The resulting hybrid silkworms are larger than Kraig’s original transgenic silkworms and are also producing significantly larger recombinant silk cocoons.

Independent laboratory testing confirmed that the transgenic/commercial silkworm hybrids are producing silk which is significantly stronger and more flexible than that of the original commercial strain. The new recombinant spider silk is a composite silk composed of both native silkworm silk proteins and spider silk proteins (as in the original Kraig transgenic silkworm whose development was announced in late September).

Kim Thompson, the Company’s CEO and Founder, stated, “The new hybrid was specifically designed for commercialization and has been designated ‘Monster Hybrid,’ which is the successful cross between our transgenic silkworms and a much larger commercial strain.

“The result is a large, robust, commercial sized silkworm which spins a larger commercial sized cocoon composed of recombinant spider silk like the original transgenic. The new hybrid was specifically designed to generate greater recombinant silk production capacity than our original first generation transgenic.”

“This larger hybrid transgenic will be the platform for our commercialization ramp up,” Thompson continued. “Now that the strength and elasticity qualities have been confirmed, we can move forward with cultivating the hybrids in commercially viable quantities. We are working diligently to increase our stock of the new strain in order to increase our production capacity.”

About Kraig Biocraft Laboratories

Kraig Biocraft Laboratories is a fully reporting biotechnology company that recently achieved a series of scientific breakthroughs, with implications for the global textile industry. For further information please visit www.KraigLabs.com .

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “hopes,” “develops,” “researching,” “research,” “potential,” “could” or other words or phrases of similar import. Similarly, statements in this release that describe the Company’s business strategy, outlook, objectives, plans, intentions or goals should all be considered forward-looking statements. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. Management cautions that its ability to further its research, and create commercially-viable products may be affected by the competitive environment, the Company’s financial condition and its ability to raise sufficient capital to meet the financial obligations of its business plan and to fund its continuing operations.

Contact: Ben Hansel (720) 288-8495

LANSING, MI, May 25, 2011 — Kraig Biocraft Laboratories, Inc. (PINKSHEETS: KBLB) announces today that Kim Thompson cordially invites all interested parties to participate in the Company’s conference call to be held on Friday, June 10, 2011 at 4:30 p.m. EDT.

Thompson, the Company’s CEO and Founder, will review the recent Sigma-Aldrich agreement and upcoming laboratory developments, as well as what is in the recombinant spider silk commercialization pipeline, followed by a question and answer period.

The conference call phone number and other details, including access codes, will be announced in a follow-up company release on the morning of the call. Shareholders are invited to submit questions to benh@ttfsco.com and must be received by Thursday, June 9, to be considered.

About Kraig Biocraft Laboratories

Kraig Biocraft Laboratories is a fully reporting biotechnology company that recently achieved a series of scientific breakthroughs, with implications for the global textile industry. For further information please visit www.KraigLabs.com .

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “hopes,” “develops,” “researching,” “research,” “potential,” “could” or other words or phrases of similar import. Similarly, statements in this release that describe the Company’s business strategy, outlook, objectives, plans, intentions or goals should all be considered forward-looking statements. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. Management cautions that its ability to further its research, and create commercially-viable products may be affected by the competitive environment, the Company’s financial condition and its ability to raise sufficient capital to meet the financial obligations of its business plan and to fund its continuing operations.

Contact: Ben Hansel (720) 288-8495

Sigma-Aldrich and Kraig to work together to create the next generation biomaterials.

Sigma-Aldrich Becomes Kraig Shareholder

  LANSING , MI –4/12/2011 – Kraig Biocraft Laboratories, Inc. (Pinksheets: KBLB) announced today that the Company has entered into a licensing agreement with biotechnology giant Sigma-Aldrich (NASDAQ: SIAL), Inc.

Kraig has successfully negotiated a license to use Sigma-Aldrich’s powerful zinc finger technology to accelerate its scientific research and product development, along with an option to commercialize the resulting biomaterials in the textile and biomedical fields.

“Sigma-Aldrich’s proprietary zinc finger technologies are extremely powerful tools which enable very precise genetic targeting,” said Kraig’s CEO Kim Thompson. “We are convinced that this technology is the key to creating advanced new products and materials. We believe that when these customized tools are delivered by Sigma in the coming weeks, the technology will enable us to rapidly and precisely target specific gene sequences for the creation of stronger fibers, advanced textiles and new bio-materials.”

“ZFN technology has been revolutionary in genome engineering for various applications, including animal models of disease, engineering of biopharmaceutical production systems, academic research and therapeutics,” said Dr. Joseph Bedell, Director of Sigma’s Commercial Animal Technology Group. “Spider silk production is just the first example of a commercial animal application for this exciting technology.”

“Kraig has the utmost confidence in the power of Sigma’s zinc finger technology,” said Mr. Thompson. “Sigma’s agreeing to provide this technology by virtue of the licensing agreement to Kraig, is a real boost for us, and for the future of bio-materials and spider silk technology. We negotiated this agreement not only to accelerate our development of advanced materials, but also because I believe that Sigma’s zinc finger technology will reinforce Kraig’s competitive advantage in the field of bio-materials and advanced silk polymers. Kraig Biocraft Laboratories expectation is that the combination of Sigma-Aldrich’s revolutionary technology and know-how, coupled with Kraig’s proprietary bio-materials technology and know-how, will create synergies that will benefit both companies.

About Sigma-Aldrich

Sigma- Aldrich is a leading Life Science and High Technology company. Its biochemical and organic chemical products and kits are used in scientific research, including genomic and proteomic research, biotechnology, pharmaceutical development and as key components in pharmaceutical, diagnostic and other high technology manufacturing. The Company has customers in life science companies, university and government institutions, hospitals, and in industry. Over one million scientists and technologists use its products. Sigma- Aldrich operates in 38 countries and has 7,900 employees providing excellent service worldwide. Sigma- Aldrich is committed to Accelerating Customer Success through Innovation and Leadership in Life Science, High Technology and Service. For more information about Sigma-Aldrich, please visit its award-winning Web site at http://www.sigma-aldrich.com .

About Kraig Biocraft Laboratories

Kraig Biocraft Laboratories is a fully reporting biotechnology company that recently achieved a series of scientific breakthroughs, with implications for the global textile industry. For further information please visit www.KraigLabs.com .

Statements in this press release about the company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “hopes,” “develops,” “researching,” “research,” “potential,” “implications,” “could” or other words or phrases of similar import. Similarly, statements in this release that describe the Company’s business strategy, outlook, objectives, plans, intentions or goals should all be considered forward-looking statements. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. Management cautions that its ability to further its research, and create commercially-viable products may be affected by the competitive environment, the Company’s financial condition and its ability to raise sufficient capital to meet the financial obligations of its business plan and to fund its continuing operations.

Contact:
Ben Hansel
(720) 288-8495 benh@ttfsco.com

See Sigma-Aldrich’s related press release

Sigma’s CompoZr ® ZFN technology expected to enable targeted insertion of spider silk genes and the removal of endogenous silkworm genes

 St. Louis, MO. – April 12, 2011 – Sigma Life Science, the innovative biological products and services research business of Sigma-Aldrich ® (Nasdaq:SIAL), today announced the signing of an agreement with Kraig Biocraft Laboratories, Inc. (KBLB) to develop genetically modified silkworms for the production of spider silk, using Sigma’s proprietary CompoZr Zinc Finger Nuclease (ZFN) technology. The transfer of silk genes from the spider to the silkworm is expected to allow the mass production of silk with enhanced strength and elasticity with potential textiles and biomedical applications, such as sutures, tendon and ligament repair, bulletproof vests, and automobile airbags.

Since the first published sequence of a spider silk gene in 1990, much research has focused on the production of commercially viable spider silk with high tensile strength and elasticity. In 2010 KBLB made an important advance towards this goal, by producing hybrid silkworms with randomly inserted spider silk genes, yielding hybrid spider­silkworm silk with greater strength and durability than native silkworm silk. The precise gene targeting and high efficiency of Sigma’s ZFN technology allow s KBLB to build on its revolutionary proof of concept research, by concomitantly targeting the insertion of spider silk genes into the silkworm genome while removing endogenous silkworm silk genes. The resulting transgenic silkworm is expected to be capable of spinning pure spider silk at commercially viable production levels.

“ZFN technology has been revolutionary in genome engineering for various applications, including animal models of disease, engineering of biopharmaceutical production systems, academic research and therapeutics,” said Dr. Joseph Bedell, Director of Sigma Life Science’s Commercial Animal Technologies Group. “Spider silk production is just the first example of a potential commercial animal application for this exciting technology, perfectly positioning Sigma Life Science as a leading provider of innovative technologies that are changing the face of science and improving the quality of life.”

Cautionary statement: The foregoing release contains forward-looking statements that can be identified by terminology such as “expected,” “allows,” “potential,” or similar expressions, or by expressed or implied discussions regarding potential future revenues from products derived there from. You should not place undue reliance on these statements. Such forward-looking statements reflect the current views of management regarding future events, and involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guarantee that CompoZr Zinc Finger Nuclease technology will assist the Company to achieve any particular levels of revenue in the future. In particular, management’s expectations regarding products associated with CompoZr Zinc Finger Nuclease technology, including those related to silk production, could be affected by, among other things, unexpected regulatory actions or delays or government regulation generally; the Company’s ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry and general public pricing pressures; the impact that the foregoing factors could have on the values attributed to the Company’s assets and liabilities as recorded in its consolidated balance sheet, and other risks and factors referred to in Sigma-Aldrich’s current Form 10-K on file with the US Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, believed, estimated or expected. Sigma-Aldrich is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

About Sigma Life Science: Sigma Life Science is a Sigma-Aldrich business that represents the Company’s leadership in innovative biological products and services for the global life science market and offers an array of biologically-rich products and reagents that researchers use in scientific investigation. Product areas include biomolecules, genomics and functional genomics, cells and cell-based assays, transgenics, protein assays, stem cell research, epigenetics and custom services/oligonucleotides. Sigma Life Science also provides an extensive range critical bioessentials like biochemicals, antibiotics, buffers, carbohydrates, enzymes, forensic tools, hematology and histology, nucleotides, amino acids and their derivatives, and cell culture media.

About Sigma-Aldrich: Sigma-Aldrich is a leading Life Science and High Technology company committed to Enabling Science to Improve the Quality of Life. Its chemical and biochemical products and kits are used in scientific research, including genomic and proteomic research, biotechnology, pharmaceutical development and as key components in pharmaceutical, diagnostic and other high technology manufacturing. The Company has customers in life science companies, university and government institutions, hospitals, and in industry. Over one million scientists and technologists use its products. Sigma-Aldrich operates in 40 countries and has 7 9 00 employees providing excellent service worldwide. For more information about Sigma-Aldrich, please visit its award-winning Web site at http://www.sigma-aldrich.com .

Sigma-Aldrich and Sigma are trademarks of Sigma-Aldrich Biotechnology L.P. and Sigma-Aldrich Co.

 See KBLB’s related press release

Kraig Adds Renowned Textile Expert and Former DuPont Textiles Research Director to Its Advisory Board

LANSING, MI, Jan 24, 2011 — Kraig Biocraft Laboratories, Inc. (PINKSHEETS: KBLB) announced today that Dr. Joe Cunning, a leading figure in the textile industry and member of the Textile Institute’s governing board, with 45 years of experience in the fibers, textile and apparel industry, has joined the Company’s Board of Advisors.

For the last 20 years Dr. Cunning has been the President of Cunning & Associates, Ltd., a leading textile industry consulting firm. He also completed a highly successful 28 year career at DuPont, where he headed the pioneering research laboratory in Wilmington, and was in charge of worldwide research on all fiber types. His manufacturing experience included worldwide responsibility for non-woven products, as well as polyester filament and staple fibers.

Dr. Cunning was awarded the Textile Institute’s Medal for outstanding contribution to the industry in 2000 and in 2010 he was presented with the Textile Institute’s Companion Membership award, as one of fifty living persons who have made a significant impact on the textile industry.

In addition to his work on various corporate boards, Dr. Cunning served on the governing boards of the Fiber Society, vice-president of the Textile Institute, the Technical Advisory Committee, and on the board of governors of the Iowa State University Foundation. In 1992, Cunning was named the National Textile Center’s (a research consortium of eight universities) first Executive Director, a post he held for 12 years.

“Dr Cunning brings a wealth of knowledge and textile industry expertise, which is exactly what we need as we move to commercialize our laboratory discoveries,” said Kraig Biocraft Laboratories founder and CEO, Kim K. Thompson. “He is highly respected by the industry leaders, which I believe will be instrumental as we seek new opportunities and partnerships.”

“Joe’s Textile Institute Companion Membership induction is a testament to his remarkable textile industry accomplishments and his innovative leadership record. We are fortunate to attract someone with his level of expertise, and talent, for his new role with the Company.”

Kraig Biocraft Laboratories is a fully reporting biotechnology company that recently achieved a series of scientific breakthroughs, with implications for the global textile industry. For further information, including videos, which outline the commercial potential that has garnered attention of many scientific and trade journals, please visit www.KraigLabs.com .

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “hopes,” “develops,” “researching,” “research,” “potential,” “implications,” “could” or other words or phrases of similar import. Similarly, statements in this release that describe the Company’s business strategy, outlook, objectives, plans, intentions or goals should all be considered forward-looking statements. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. Management cautions that its ability to further its research, and create commercially-viable products may be affected by the competitive environment, the Company’s financial condition and its ability to raise sufficient capital to meet the financial obligations of its business plan and to fund its continuing operations.

Contact: Ben Hansel (720) 288-8495